DealsSK Capital’s Apotex to acquire Canadian rights to ToripalimabToripalimab is an anti-PD-1 monoclonal antibody.ByIrien Joseph3 July 2024•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsCanadaNorth AmericaHealthcareBriefs